Therapicon Srl
Main menu:
Antimetastatic effect on human cell disorders
Method for using recombinant human lysozyme (rHLys) from genetic engineering to control life-threatening diseases associated with abnormal cell proliferation and migration, such as cancer metastasis, by administering therapeutically effective doses of recombinant human lysozyme to elicit said antimetastatic effects.
Therapicon® is a registered trade-mark in Italy and at OMPI (WIPO)-Geneva